Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04467281 | A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT02272803 | Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT03841565 | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT02977494 | Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment(GMMG-DANTE) | completed | Phase 2 | 22 | Universitätsklinikum Hamburg-EppendorfOTHER | 2 | May 31, 2022 | clinicaltrials |
| NCT01849783 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | completed | Phase 2 | 41 | Margarida Magalhaes-SilvermanOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03256045 | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT01463670 | Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance | completed | Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT01658241 | Panobinostat Biological Correlates Study(VEG VCA1) | completed | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05170789 | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma(ESdRRMM) | withdrawn | Phase 2 | 0 | Tulane University School of MedicineOTHER | 0 | May 4, 2022 | clinicaltrials |
| NCT04361851 | Study of Dara-Pembro for Multiple Myeloma Patients | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT04230031 | Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT03964688 | Effect of Vitamin C in Autologous Stem Cell Transplantations(VICAST) | completed | Phase 2 | 47 | Maastricht University Medical CenterOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03850522 | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | terminated | Phase 2 | 6 | Lene Meldgaard KnudsenOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03312868 | Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma | terminated | Phase 2 | 10 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | terminated | Phase 2 | 13 | OncotherapeuticsINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05147493 | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | unknown | Phase 2 | 51 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT05298683 | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | unknown | Phase 2 | 108 | Hellenic Society of HematologyOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT01989598 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03697629 | A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 40 | Canadian Myeloma Research GroupOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT00792506 | Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 1 | ItalfarmacoINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT01496118 | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03875495 | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | terminated | Phase 1 / Phase 2 | 9 | Genenta ScienceINDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT02424851 | Optimising Renal Outcome in Myeloma Renal Failure(OPTIMAL) | completed | Phase 2 | 31 | Oxford University Hospitals NHS TrustOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04065789 | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients(KyDaR) | completed | Phase 2 | 41 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04150692 | Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jan 24, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 84 | Pharmacyclics LLC.INDUSTRY | 2 | Dec 21, 2021 | clinicaltrials |
| NCT05150522 | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT02086552 | Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01131169 | Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions | completed | Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT01793051 | Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma | completed | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)(FUMANBA-1) | unknown | Phase 1 / Phase 2 | 132 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 23, 2021 | clinicaltrials |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 91 | MorphoSys AGINDUSTRY | 2 | Nov 16, 2021 | clinicaltrials |
| NCT00177047 | Autologous Transplant for Multiple Myeloma | completed | Phase 2 / Phase 3 | 363 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT05114109 | Isatuximab in Type I Cryoglobulinemia(ICE) | unknown | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT01054144 | Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT02951819 | A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma | completed | Phase 2 | 101 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT05054478 | Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation(PCL-2) | not yet recruiting | Phase 2 | 29 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 23, 2021 | clinicaltrials |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | terminated | Phase 2 | 39 | University of LiegeOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT02169791 | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 | completed | Phase 2 | 29 | Northside Hospital, Inc.OTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT02045017 | Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency | completed | Phase 2 | 81 | CelgeneINDUSTRY | 8 | Aug 27, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT04584307 | Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant(Immuno-POWER) | withdrawn | Phase 2 | 0 | Natalie CallendarOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01720875 | Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)(MUKfour) | completed | Phase 2 | 16 | University of LeedsOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT03634800 | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)(RISE-M) | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2022source: clinicaltrials